Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 07:16:39 15/04/2026 pm IST			5-day change	1st Jan Change
1,851.50 ^DKK	+0.46%		+3.66%	-8.53%

10:32am	Nordic Equities in North America - Astra Zeneca Gains 0.9 Percent	FW
15/04	Genmab A/S Provides Net Sales of Darzalex Results for the First Quarter of 2026	CI

Genmab increases sales and operating profit

Published on 05/08/2025 at 08:48 pm IST

Finwire - Translated by Marketscreener - See original

GENMAB A/S

+0.46%

Danish pharmaceutical company Genmab reported increased sales in the first quarter of 2025 compared with the same period last year. Operating profit increased.

Net sales rose 18.6 percent to $715 million (603).

Operating profit was $188 million (116). The operating margin was 26.3% (19.2).

Profit after tax was $195 million (192).

Genmab reiterates its guidance for the full year 2025.

Genmab, MUSD	Q1-2025	Q1	Change
Net sales	71	603	18
Operating	188	116	62.1
Operating margin	26	19
Net profit	195	192	1

Consensus data from Bloomberg

Latest news about Genmab A/S

10:32am	Nordic Equities in North America - Astra Zeneca Gains 0.9 Percent	FW
15/04	Genmab A/S Provides Net Sales of Darzalex Results for the First Quarter of 2026	CI
14/04	Genmab Posts Higher Darzalex Net Sales in Q1	MT
14/04	Genmab Reports Q1 Net Sales of DARZALEX	MT
14/04	Genmab reports Darzalex sales of $3.96 billion in Q1	FW
14/04	Genmab Q1 Darzalex net sales at $3,964 mln	RE
14/04	Jyske Bank upgrades Genmab to Buy from Hold, sets price target at DKK 2,300 - BN	FW
14/04	Genmab Combo Therapy Shows Safe Profile in Ovarian Cancer Trial	MT
13/04	Genmab Says Rinatabart Sesutecan Combination Tolerable in Patients With Advanced Ovarian Cancer	MT
13/04	Genmab reports promising safety data in clinical trial	FW
13/04	Genmab says phase 1/2 Rainfol-01 data show Rina-S and bevacizumab combination tolerable	RE
13/04	Genmab A/S Presents Safety And Tolerability Data Of Rinatabart Sesutecan (Rina-S) In Combination With Bevacizumab In Advanced Ovarian Cancer	CI
10/04	Nordic Equities in North America - Ericsson slips 0.5 percent	FW
09/04	Nordic Equities in North America - Autoliv slips 0.7 percent	FW
07/04	Nordic Stocks in North America - Astra Zeneca rose 2.1 percent	FW

Chart Genmab A/S

Duration

Period

GMAB: Dynamic Chart

Company Profile

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).

Employees

2,973

Sector

Biotechnology & Medical Research

Calendar

07/05 - Earnings release - Q1 2026

More about the company